Overview

Clopidogrel Versus Ticagrelor in Type-2 Diabetes

Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
CLOTILDIA is a single-center, prospective, randomized, open label, cross-over study evaluating the effects of ticagrelor versus high-dose clopidogrel on endothelial function and platelet reactivity in patients with type-2 diabetes mellitus (T2DM) treated with percutaneous coronary intervention (PCI).
Phase:
Phase 4
Details
Lead Sponsor:
Campus Bio-Medico University
Treatments:
Clopidogrel
Ticagrelor
Ticlopidine